Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
Saved in:
| Title: | Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. |
|---|---|
| Authors: | Modlin IM; Yale University School of Medicine, New Haven, CT., Kidd M; Wren Laboratories, Branford, CT., Frilling A; Imperial College London, London, United Kingdom., Falconi M; IRCCS San Raffaele Scientific Institute, Milan, Italy., Filosso PL; University of Torino, Torino, Italy., Malczewska A; Medical University of Silesia, Katowice, Poland., Kitz A; Wren Laboratories, Branford, CT. |
| Source: | Annals of surgery [Ann Surg] 2021 Sep 01; Vol. 274 (3), pp. 481-490. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1528-1140 |
|---|---|
| DOI: | 10.1097/SLA.0000000000005026 |
